Treatment responses in patients with C-ALCL or LyP developing extracutaneous disease (N = 43)
| Therapy . | C-ALCL (n = 30) . | LyP (n = 13) . | Overall (N = 43) . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N . | CR . | Relapse skin limited . | Systemic relapse . | N . | CR* . | Relapse skin limited (%) . | Systemic relapse . | N . | CR . | Relapse (%) . | PFS5 (%) . | DSD5 (%) . | OS5 (%) . | |
| Anthracycline-based chemotherapy | 25 | 16/25 (64) | 3/16 (19) | 6/16 (38) | 9 | 5/9 (56) | 3/5 (60) | 0/5 (0) | 34 | 21/34 (62) | 12/21 (57) | 34 | 46 | 46 |
| RT | 3 | 3/3 (100) | 2/3 (67) | 0/3 (0) | 1 | 1/1 (100) | 1/1 (100) | 0/1 (0) | 4 | 4/4 (100) | 3/4 (75) | 100 | 0 | 100 |
| No therapy | 2 | 0/2 (0) | — | — | 3 | 1/3 (33) | 1/1 (100) | 0/1 (0) | 5 | 1/5 (20) | 1/1 (100) | 20 | 80 | 20 |
| Total | 30 | 19/30 (63) | 5/19 (26) | 6/19 (32) | 13 | 7/13 (54) | 5/7 (71) | 0/7 (0) | 43 | 26/43 (61) | 16/26 (62) | 39 | 47 | 47 |
| Therapy . | C-ALCL (n = 30) . | LyP (n = 13) . | Overall (N = 43) . | . | . | . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N . | CR . | Relapse skin limited . | Systemic relapse . | N . | CR* . | Relapse skin limited (%) . | Systemic relapse . | N . | CR . | Relapse (%) . | PFS5 (%) . | DSD5 (%) . | OS5 (%) . | |
| Anthracycline-based chemotherapy | 25 | 16/25 (64) | 3/16 (19) | 6/16 (38) | 9 | 5/9 (56) | 3/5 (60) | 0/5 (0) | 34 | 21/34 (62) | 12/21 (57) | 34 | 46 | 46 |
| RT | 3 | 3/3 (100) | 2/3 (67) | 0/3 (0) | 1 | 1/1 (100) | 1/1 (100) | 0/1 (0) | 4 | 4/4 (100) | 3/4 (75) | 100 | 0 | 100 |
| No therapy | 2 | 0/2 (0) | — | — | 3 | 1/3 (33) | 1/1 (100) | 0/1 (0) | 5 | 1/5 (20) | 1/1 (100) | 20 | 80 | 20 |
| Total | 30 | 19/30 (63) | 5/19 (26) | 6/19 (32) | 13 | 7/13 (54) | 5/7 (71) | 0/7 (0) | 43 | 26/43 (61) | 16/26 (62) | 39 | 47 | 47 |
Data are presented as n/N (%) unless otherwise indicated.
DSD5, five-year cumulative incidence of DSD.
CR refers to complete remission of extracutaneous localizations.